OUTLOOK THERAPEUTICS INC Total Liabilities

Latest as of September 2025: $50.77 Trillion USD

OUTLOOK THERAPEUTICS INC total liabilities. Based on the latest financial reports, OUTLOOK THERAPEUTICS INC (OTLK) has total liabilities worth $50.77 Trillion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check OTLK financial resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of OUTLOOK THERAPEUTICS INC (2014–2025)

Total liabilities of OUTLOOK THERAPEUTICS INC from 2014 to 2025. This chart illustrates how OUTLOOK THERAPEUTICS INC's total liabilities have evolved over time, based on quarterly financial data. Explore OTLK strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

OUTLOOK THERAPEUTICS INC Competitors by Total Liabilities

The table below lists competitors of OUTLOOK THERAPEUTICS INC ranked by their total liabilities.

Company Country Total Liabilities
IFirma SA
WAR:IFI
Poland zł10.94 Million
Nephros Inc
NASDAQ:NEPH
USA $3.09 Million
Samhwa Crown
KO:004450
Korea ₩96.55 Billion
Thirdeye Systems Ltd
TA:THES
Israel ILA31.28 Million
JT Corporation
KQ:089790
Korea ₩28.41 Billion
B. Gaon Holdings Ltd
TA:GAON
Israel ILA639.93 Million
Total Soft Bank Ltd
KQ:045340
Korea ₩19.09 Billion
BYC Co Ltd
KO:001465
Korea ₩215.32 Billion

Liability Composition Analysis (2014–2025)

This chart breaks down OUTLOOK THERAPEUTICS INC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see OUTLOOK THERAPEUTICS INC assets under control.

Liquidity & Leverage Metrics

OUTLOOK THERAPEUTICS INC Total Liabilities Ratios Explained

OUTLOOK THERAPEUTICS INC total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 0.38 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1577369.79 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 2.73 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how OUTLOOK THERAPEUTICS INC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for OUTLOOK THERAPEUTICS INC (2014–2025)

The table below shows the annual total liabilities of OUTLOOK THERAPEUTICS INC from 2014 to 2025.

Year Total Liabilities Change
2025-09-30 $50.77 Trillion +49825230.14%
2024-09-30 $101.90 Million +118.02%
2023-09-30 $46.74 Million +136.16%
2022-09-30 $19.79 Million +8.72%
2021-09-30 $18.20 Million +7.67%
2020-09-30 $16.91 Million -39.41%
2019-09-30 $27.90 Million -35.25%
2018-09-30 $43.09 Million -16.26%
2017-09-30 $51.46 Million +78.03%
2016-09-30 $28.91 Million -17.77%
2015-09-30 $35.15 Million -45.30%
2014-09-30 $64.26 Million --

About OUTLOOK THERAPEUTICS INC

NASDAQ:OTLK USA Biotechnology
Market Cap
$34.40 Million
Market Cap Rank
#23111 Global
#5070 in USA
Share Price
$0.47
Change (1 day)
-5.17%
52-Week Range
$0.20 - $2.47
All Time High
$867.20
About

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other … Read more